Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

Drug susceptibility and mutations in the reverse transcriptase (RT) gene were analyzed with 167 virus isolates from 38 patients treated with nevirapine, a potent nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) RT. Resistant isolates emerged quickly and uniformly in all patients administered nevirapine either as monotherapy or in combination with zidovudine (AZT). Resistance developed as early as 1 week, indicating rapid turnover of the virus population. The development of resistance was associated with the loss of antiviral drug activity as measured by CD4 lymphocyte counts and levels of HIV p24 antigen and RNA in serum. In addition to mutations at amino acid residues 103, 106, and 181 that had been identified by selection in cell culture, mutations at residues 108, 188, and 190 were also found in the patient isolates. Sequences from patient clones documented cocirculating mixtures of populations of different mutants. The most common mutation with monotherapy, tyrosine to cysteine at residue 181, was prevented from emerging by coadministration of AZT, which resulted in the selection of alternative mutations. The observations documented that, under selective drug pressure, the circulating virus population can change rapidly, and many alternative mutants can emerge, often in complex mixtures. The addition of a second RT inhibitor, AZT, significantly altered the pattern of mutations in the circulating population of HIV.

[1]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[2]  B. Larder.  3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors , 1992, Antimicrobial Agents and Chemotherapy.

[3]  F. Corpet.  Multiple sequence alignment with hierarchical clustering. , 1988, Nucleic acids research.

[4]  Roy E. Byington,et al.  Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. , 1991, Disease markers.

[5]  E A Emini,et al.  Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. , 1992, The Journal of biological chemistry.

[6]  E. De Clercq,et al.  Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy , 1993, Journal of virology.

[7]  J. Balzarini,et al.  Treatment ofHumanImmunodeficiency VirusType1 (HIV-1)-Infected Cells withCombinations ofHIV-1-Specific Inhibitors Results ina Different Resistance Pattern Than DoesTreatment withSingle-Drug Therapy , 1993 .

[8]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.

[9]  D. Ho,et al.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.

[10]  D. Richman,et al.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[12]  J. Coffin,et al.  Genetic diversity and evolution of retroviruses. , 1992, Current topics in microbiology and immunology.

[13]  S. Broder,et al.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.

[14]  D. Richman,et al.  Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. , 1993, The Journal of biological chemistry.

[15]  M. Hirsch,et al.  Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro , 1992, Antimicrobial Agents and Chemotherapy.

[16]  B. Larder,et al.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Condra,et al.  HIV and multidrug resistance , 1993, Nature.

[18]  J. Condra,et al.  Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors , 1993, Antimicrobial Agents and Chemotherapy.

[19]  J L Sullivan,et al.  Pharmacokinetics of nevirapine: initial single-rising-dose study in humans , 1993, Antimicrobial Agents and Chemotherapy.

[20]  A. Bacolla,et al.  Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Michael S. Saag,et al.  A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1993 .

[22]  D. Richman,et al.  BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine , 1991, Antimicrobial Agents and Chemotherapy.

[23]  S D Kemp,et al.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.

[24]  Anthony S. Fauci,et al.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.

[25]  J. Proudfoot,et al.  A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. , 1991, Biochemistry.

[26]  J. Holland,et al.  RNA virus populations as quasispecies. , 1992, Current topics in microbiology and immunology.

[27]  Paul Kellam,et al.  Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro , 1993, Nature.

[28]  E A Emini,et al.  Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors , 1991, Journal of virology.

[29]  J. Adams,et al.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. , 1990, Science.

[30]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[31]  D. Richman,et al.  The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. , 1989, The Journal of infectious diseases.

[32]  Florence Corpet,et al.  Multiple sequence alignment withhierarchical clustering , 1988 .

[33]  I. Chen,et al.  A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Richman,et al.  Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. , 1994, Journal of acquired immune deficiency syndromes.